About Us

Enteris BioPharma is a clinical stage biopharmaceutical company offering innovative formulation solutions built around its proprietary drug delivery technologies.

Enteris BioPharma operates as an independent, wholly-owned subsidiary of SWK Holdings Corporation (SWKH.OB). Since its founding in 2013, Enteris has advanced multiple internal and external programs leveraging its Peptelligence® platform. The technology has been developed and proven effective over the last decade to enable the safe oral delivery of peptide-based therapeutics as well as other molecules with low oral bioavailability.

Currently, Enteris BioPharma’s internal product pipeline consists of Ovarest® (oral leuprolide tablet), currently being evaluated in for endometriosis, and Tobrate™ (oral tobramycin tablet) for the treatment of uncomplicated urinary tract infection (uUTI). External market analyses demonstrate projected annual U.S. revenue potential for these two products in excess of $1 billion in aggregate.

Additionally, Enteris BioPharma’s oral peptide delivery technology is the subject of several active external development programs, the most advanced of which include R-Pharm’s TBRIA, an oral calcitonin for patients with postmenopausal osteoporosis, and an oral formulation of Cara Therapeutics’ KORSUVA™, a potent peripheral kappa opioid receptor agonist for chronic pain and pruritus.